Investing.com - PTC Therapeutics (NASDAQ: PTCT) reported second quarter EPS of $-1.29, $0.17 worse than the analyst estimate of $-1.12. Revenue for the quarter came in at $186.7M versus the consensus estimate of $183.28M.
PTC Therapeutics's stock price closed at $32.45. It is up 0.62% in the last 3 months and down -18.57% in the last 12 months.
PTC Therapeutics saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See PTC Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, PTC Therapeutics's Financial Health score is "good performance".
Check out PTC Therapeutics's recent earnings performance, and PTC Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar